Literature DB >> 18343748

Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days.

R Paris1, M Confalonieri, R Dal Negro, G P Ligia, L Mos, T Todisco, V Rastelli, G Perna, M Cepparulo.   

Abstract

This randomised, open-label, non-inferiority study was designed to demonstrate that a 3-day course of oral azithromycin 1 g once daily was at least as effective as a standard 7-day course of oral amoxicillin-clavulanate 875/125 mg twice daily in the treatment of outpatients with community-acquired pneumonia (Fine class I and II). In total, 267 patients with clinically and radiologically confirmed community-acquired pneumonia were randomly assigned to receive either the azithromycin (n=136) or the amoxicillin-clavulanate (n=131) regimen. At screening, 60/136 (58.8%) and 61/131 (62.9%) respectively had at least one pathogen identified by sputum culture, PCR, or serology. The primary endpoint was the clinical response in the intent-to-treat population at the end of therapy (day 8 to 12). Clinical success rates were 126/136 (92.6%) for azithromycin and 122/131 (93.1%) for amoxicillin-clavulanate (treatment difference: - 0.48%; 95% confidence interval: - 5.66%; 4.69%). Clinical and radiological success rates at follow-up (day 22-26) were consistent with the end of therapy results, no patient reporting clinical relapse. Bacteriological success rates at the end of therapy were 32/35 (91.4%) for azithromycin and 30/33 (90.9%) for amoxicillin-clavulanate (treatment difference: 0.52%; 95% confidence interval - 10.81%; 11.85%). Both treatment regimens were well tolerated: the overall incidence of adverse events was 34/136 (25.0%) for azithromycin and 22/132 (16.7%) for amoxicillin-clavulanate. In both treatment groups, the most commonly reported events were gastrointestinal symptoms. Azithromycin 1g once daily for 3 days is at least as effective as amoxicillin-clavulanate 875/125 mg twice daily for 7 days in the treatment of adult patients with community-acquired pneumonia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18343748     DOI: 10.1179/joc.2008.20.1.77

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  8 in total

Review 1.  Assessment of bias in outcomes reported in trials on pneumonia: a systematic review.

Authors:  T Avni; S Shiber-Ofer; L Leibovici; M Paul
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-12-19       Impact factor: 3.267

2.  Influence of body weight, ethnicity, oral contraceptives, and pregnancy on the pharmacokinetics of azithromycin in women of childbearing age.

Authors:  James H Fischer; Gloria E Sarto; Mitra Habibi; Sarah J Kilpatrick; Ruth E Tuomala; Janice M Shier; Lori Wollett; Patricia A Fischer; Kinnari S Khorana; Keith A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2011-11-21       Impact factor: 5.191

3.  Systematic Review and Meta-analysis of the Efficacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia in Adults.

Authors:  Giannoula S Tansarli; Eleftherios Mylonakis
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

4.  Shorter versus longer durations of antibiotic treatment for patients with community-acquired pneumonia: a protocol for a systematic review and meta-analysis.

Authors:  Arnav Agarwal; Ya Gao; Luis Enrique Colunga Lozano; Saad Asif; Layla Bakaa; Maryam Ghadimi; John Basmaji; Aninditee Das; Mark Loeb; Gordon Guyatt
Journal:  BMJ Open       Date:  2022-06-24       Impact factor: 3.006

5.  Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations.

Authors:  Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; Navneet Singh; Narayan Mishra; G C Khilnani; J K Samaria; S N Gaur; S K Jindal
Journal:  Lung India       Date:  2012-07

6.  The fitness cost of antibiotic resistance in Streptococcus pneumoniae: insight from the field.

Authors:  M Cyrus Maher; Wondu Alemayehu; Takele Lakew; Bruce D Gaynor; Sara Haug; Vicky Cevallos; Jeremy D Keenan; Thomas M Lietman; Travis C Porco
Journal:  PLoS One       Date:  2012-01-17       Impact factor: 3.240

7.  Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.

Authors:  Joshua P Metlay; Grant W Waterer; Ann C Long; Antonio Anzueto; Jan Brozek; Kristina Crothers; Laura A Cooley; Nathan C Dean; Michael J Fine; Scott A Flanders; Marie R Griffin; Mark L Metersky; Daniel M Musher; Marcos I Restrepo; Cynthia G Whitney
Journal:  Am J Respir Crit Care Med       Date:  2019-10-01       Impact factor: 21.405

Review 8.  Comparing Several Treatments with Antibiotics for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Fusheng Bai; Xinming Li
Journal:  Iran J Public Health       Date:  2021-06       Impact factor: 1.429

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.